Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen which mediates its effects by binding to tyrosine kinase receptors. We have characterized the VEGF-activated intracellular signal transduction pathway in bovine aortic endothelial cells and correlated this to its mitogenic effects. VEGF induced concentration- and time-dependent increases in protein kinase C (PKC) activation with a maximum of 2.2-fold above the basal level at 5 x 10(-10) M within 10 min as measured both by in situ and translocation assays. Immunoblotting analysis of PKC isoforms in cytosolic and membrane fractions indicated that after VEGF stimulation the content of Ca(2+)-sensitive PKC isoforms (alpha and betaII) was increased in the membrane fractions, whereas no changes were observed for PKC isoforms delta and epsilon. The stimulation of PKC activity by VEGF was preceded by the activation of phospholipase Cgamma (PLCgamma). This was demonstrated by parallel increases in PLCgamma tyrosine phosphorylation, [3H]inositol phosphate production, and [3H]arachidonic acid-labeled diacylglycerol formation in bovine aortic endothelial cells. In addition, VEGF increased phosphatidylinositol 3-kinase activity 2.1-fold which was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, without decreasing the VEGF-induced increase in PKC activity or endothelial cell growth. Interestingly, genistein, a tyrosine kinase inhibitor, and GFX or H-7, PKC inhibitors, abolished both VEGF-induced PKC activation and endothelial cell proliferation. VEGF's mitogenic effect was inhibited by a PKC isoform beta-selective inhibitor, LY333531, in a concentration-dependent manner. In contrast, antisense PKC-alpha oligonucleotides enhanced VEGF-stimulated cell growth with a simultaneous decrease of 70% in PKC-alpha protein content. Thus, VEGF appears to mediate its mitogenic effects partly through the activation of the PLCgamma and PKC pathway, involving predominately PKC-beta isoform activation in endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, within the TME, PKC beta, another PKC isoform, is a well‐documented effector of the VEGF signaling that promotes angiogenesis and is required for invasiveness in certain tumors, such as pancreatic tumors [122, 123, 124].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 2×
“and assayed by the method of Bradford (19).”
MethodInfluentialA RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“The cells were scraped and total lipids were extracted with chloroform according to the methods of Bligh and Dyer (22).”
MethodVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“VEGF was independently isolated as both an endothelial cell growth factor (1) and as a vasopermeability factor (3).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472 · cited 4×
“In contrast, PKC isoforms e and d, which lack Ca(21) binding sites, are only responsive to DAG and did not translocate adequately for our antibodies to detect (25).”
BackgroundMethodInfluentialAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793 · cited 2×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
BackgroundSelf-citationGenistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724 · cited 1×
“The addition of genistein (40 mm), a tyrosine kinase inhibitor (27), significantly reduced the VEGF-induced tyrosine phosphorylation of PLCg.”
BackgroundOncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694 · cited 2×
“Since PI 3-kinase has been shown to be associated with several different tyrosine kinase receptors (29), and VEGF has been reported to increase PI 3-kinase tyrosine phosphorylation (12, 13), we determined whether PI 3-kinase activity could also be activated by VEGF.”
BackgroundThe bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275 · cited 1×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
Background
Cited by
Items 401–500 of 615
Félétou, M., Staczek, J., & Duhault, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703941 · Cited by 16
Osicka, T. M., Russo, L. M., Qiu, M.-L., Brammar, G. C., Thallas, V., Forbes, J. M., Comper, W. D., & Jerums, G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200312000-00029 · Cited by 16
Spalding, A. C., Zeitlin, B. D., Wilder-Romans, K., Davis, M. E., Nor, J. E., Lawrence, T. S., & Ben‐Josef, E. (2008) · Translational Oncology · doi:10.1593/tlo.08151 · Cited by 15
“Enz is a potent and selective inhibitor of PKCβ, a predominant mediator of VEGF-induced endothelial cell proliferation and survival [33,34].”
BackgroundSakthivel, R., Zhang, J.-C., Strickland, D. K., Gåfvels, M. E., & McCrae, K. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003953200 · Cited by 15
Waksmunski, A. R., Grunin, M., Kinzy, T. G., Igo, R. P., Haines, J. L., Cooke Bailey, J. N., & for the International Age-Related Macular Degeneration Genomics Consortium (2019) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.19-27827 · Cited by 14
Insights into gene therapy for critical limb ischemia: The devil is in the details
Madonna, R., & Rokosh, G. D. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.05.001 · Cited by 14
Medical treatment of diabetic retinopathy
Donaldson, M., & Dodson, P. M. (2003) · Eye · doi:10.1038/sj.eye.6700586 · Cited by 14
Alterations in protein tyrosine kinase pathways following retinal vein occlusion in the rat
Hayashi, A., Kim, H. C., & de Juan, E. (1999) · Current Eye Research · doi:10.1076/ceyr.18.3.231.5369 · Cited by 14
Angiogenesis and Prostate Cancer
Joseph, I. B. J., & Isaacs, J. T. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-009-4_17 · Cited by 14
Salgia, R., Loganathan, S., Kanteti, R., Siddiqui, S., El‐Hashani, E., Tretiakova, M., Vigneswaran, H., Cervantes, G. M., Natarajan, V., Husain, A., et al. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.77274 · Cited by 13
“An important downstream signal transducer in the VEGF/VEGFR signaling pathway is PKC-β.[4-5] PKC-β in turn activates the Mitogen-activated protein (MAP) kinase pathway which ultimately promotes neovascularization and angiogenesis.”
Stephan, A., Suhrmann, J.-H., Skowron, M. A., Che, Y., Poschmann, G., Petzsch, P., Kresbach, C., Wruck, W., Pongratanakul, P., Adjaye, J., et al. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.06.001 · Cited by 13
Schumann, P., von See, C., Kampmann, A., Lindhorst, D., Tavassol, F., Kokemüller, H., Bormann, K., Gellrich, N., & Rücker, M. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33069 · Cited by 13
Vascular Permeability in Diabetic Retinopathy
Antonetti, D. A., VanGuilder, H. D., & Mao-Lin, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-563-3_14 · Cited by 13
“Protein kinase C β (PKCβ) acts downstream of VEGF ( 101 ) and inhibitors of this kinase can block VEGF-induced permeability (102).”
BackgroundFunatsu, H., Yamashita, T., & Yamashita, H. (2006) · Advances in clinical chemistry · doi:10.1016/s0065-2423(06)42004-7 · Cited by 13
Molecular mechanisms of growth factor action in diabetic retinopathy
Aiello, L. P., & Hata, Y. (1999) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-199904000-00011 · Cited by 13
Self-citationDesroches‐Castan, A., Quélard, D., Demeunynck, M., Constant, J., Dong, C., Kéramidas, M., Coll, J., Barette, C., Lafanéchère, L., & Feige, J. (2015) · Oncotarget · doi:10.18632/oncotarget.2979 · Cited by 12
“In agreement with these statements, we observed that chemical inhibitors of PKC (Gö6976+Gö6983), completely inhibited VEGFinduced ERK1/2 phosphorylation in HUVECs whereas they only partially inhibited FGF2-induced ERK1/2 Oncotarget5394www.impactjournals.com/oncotarget Oncotarget5395www.impactjournals.com/oncotarget ph…”
BackgroundInfluentialProtein kinase C beta in malignant pleural mesothelioma
Faoro, L. N., Loganathan, S., Westerhoff, M. A., Modi, R., Husain, A. N., Tretiakova, M., Seiwert, T. Y., Kindler, H. L., Vokes, E. E., & Salgia, R. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32830ce506 · Cited by 12
Acortatarin A inhibits high glucose-induced extracellular matrix production in mesangial cells
Zhao, Z., Li-li, Z. H. O. U., Chen, X., Cheng, Y., Hou, F. F., & Jing, N. I. E. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20122445 · Cited by 12
Serotonin-stimulated increase in cytosolic Ca2+ in cultured rat heart endothelial cells
Lee, H., & Wu, C. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00672-x · Cited by 12
Vogl, U. M., Berger, W., Micksche, M., Pirker, C., Lamm, W. W., Pichelmeyer, O., Zielinski, C. C., & Schmidinger, M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.013 · Cited by 12
He, Z., & King, G. L. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2803 · Cited by 12
Self-citationRuboxistaurin for Diabetic Retinopathy
Gardner, T. W., & Antonetti, D. A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.003 · Cited by 12
Cui, J., Shi, E., Wang, Y., & Liu, T. (2023) · Bioscience Reports · doi:10.1042/bsr20220893 · Cited by 11
Thill, M., Berna, M. J., Kunst, F., Wege, H., Strunnikova, N. V., Gordiyenko, N., Grierson, R., Richard, G. W., & Csaky, K. G. (2011) · PubMed Central · Cited by 11
Differential activations of PKC/PKA related to microvasculopathy in diabetic GK rats
Wang, H., Jiang, Y., Zhang, W., Xu, S., Liu, H., Yang, W., & Lou, J. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00184.2011 · Cited by 11
Bardal, S. K., Misurski, D. A., Qiu, X. K., Desai, K. M., & McNeill, J. R. (2006) · Diabetologia · doi:10.1007/s00125-006-0151-5 · Cited by 11
“The ability of VEGF to activate protein kinase C, through both flt-1 and flk-1 receptors, has been reported [33].”
BackgroundPotential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Mischiati, C., Melloni, E., Corallini, F., Milani, D., Bergamini, C. M., & Vaccarezza, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785294618 · Cited by 11
Role of protein kinase C in diabetic complications
King, G. L., & Daş-Evcimen, N. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.74 · Cited by 11
Self-citationMechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies
HE, Z. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90041-1 · Cited by 10
Novel therapies, including enzastaurin, in the treatment of ovarian cancer
Vergote, I. B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.900542 · Cited by 10
“PKCb is a key component of the VEGF signaling pathway that is critical in tumor angiogenesis [81,82].”
BackgroundJesmin, S., Maeda, S., Mowa, C. N., Zaedi, S., Togashi, H., Prodhan, S. H., Yamaguchi, T., Yoshioka, M., Sakuma, I., Miyauchi, T., et al. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.023 · Cited by 10
PKC and the Control of Apoptosis
Reyland, M. E., & Bradford, A. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-543-9_9 · Cited by 10
Ali, M. H. M., Draman, N., Mohamed, W. M. I. W., Yaakub, A., & Zunaina, E. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.03.002 · Cited by 10
Negative regulatory role of PI3‐Kinase in TNF‐induced tumor necrosis
Matschurat, S., Blum, S., Mitnacht‐Kraus, R., Dijkman, H. B. P. M., Kanal, L., de Waal, R. M. W., & Clauss, M. A. (2003) · International Journal of Cancer · doi:10.1002/ijc.11345 · Cited by 10
Jesmin, S., Sakuma, I., Hattori, Y., & Kitabatake, A. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000021372.99727.b3 · Cited by 10
Wang, K., Zhang, X., Tian, T., & Zhao, P. (2021) · Molecular vision · Cited by 9
Protein kinase Cδ in tumorigenesis of human malignant fibrous histiocytoma
Kawamoto, T. (2011) · Oncology Reports · doi:10.3892/or.2011.1415 · Cited by 9
“…of PKC α / β to PKC δ is an important factor in the aggressiveness of cancers (9), and other studies demonstrated that PKC β plays an important role in the signal transduction pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis in human malignancies (26,27).”
Yoo, M.-H., Yoon, Y. H., Chung, H., Cho, K. S., & Koh, J. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0395 · Cited by 9
“In the previous experiments, we also found that the reduction of endothelial cell proliferation by riluzole was mediated by the inhibition of protein kinase C (PKC) II in HUVEC culture.(14,17) These effects were confirmed in vivo in OIR in the rat.”
BackgroundThe Role of Protein Kinase C in Diabetic Retinopathy
Prakash, M., Sun, J. K., & King, G. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-563-3_8 · Cited by 9
“This suggests an important role for PKCβ in VEGFmediated cellular proliferation ( 61 , 62).”
BackgroundSelf-citationTarzami, S. T., Hsieh, S. S., Esterman, M. A., & Singh, J. P. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200501000-00005 · Cited by 9
Balakrishnan, V., & Velmurugan, D. (2012) · Bioinformation · doi:10.6026/97320630008568 · Cited by 9
Dietary and Nutritional Modulation of Tumor Angiogenesis
Mukherjee, P., Zhou, J., Sotnikov, A. V., & Clinton, S. K. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-453-5_15 · Cited by 9
Diabetic retinopathy in native and non-native Sarawakians--findings from the Diabetic Eye Registry.
Mallika, P., Aziz, S., Pp, G., Lee, P. Y., Cheah, W. L., Chong, M. S., & Ak, T. (2012) · PubMed · Cited by 8
[19] Gene delivery to cardiac muscle
Neyroud, N., Nuss, H., Leppo, M. K., Marbán, E., & Donahue, J. K. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)46064-8 · Cited by 8
Nucleoside and Nucleotide Transmission in Sensory Systems
Housley, G. D. (2001) · Springer eBooks · doi:10.1007/978-3-662-09604-8_12 · Cited by 8
Brain signalling systems: A target for treating type I diabetes mellitus
Ramakrishnan, R. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.07.017 · Cited by 7
Relationship between diabetes mellitus with dural arteriovenous fistula
Lee, D., Zhao, L. B., Shim, J. H., Lee, D. H., & Suh, D. C. (2013) · Neuroradiology · doi:10.1007/s00234-013-1221-2 · Cited by 7
“Vascular endothelial growth factor and basic fibroblast growth factor are responsible for aberrant angiogenesis in diabetic retinopathy [29] and nephropathy [30–33].”
BackgroundRíos, M. C. L. D. L., Lanza, P. A., Barbieri, C. L., González, M. L., Chabán, M. F., Soria, G., Vera, D. M. A., Carpinella, M. C., & Joray, M. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1007790 · Cited by 7
“In particular, α and β2 isozymes were found to be consistently activated as a result of VEGR-2 activation by VEGF in endothelial cells (Xia et al., 1996).”
BackgroundDias, P. F., Berti, F. V., Siqueira, J. M., Maraschin, M., Gagliardi, A. R. D. T., & Ribeiro‐do‐Valle, R. M. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0071876 · Cited by 7
Protein kinase C inhibitors in the treatment and prevention of diabetic complications
Gabriele, A., & King, G. L. (2001) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200108000-00006 · Cited by 7
Self-citationDeFouw, L. M., & DeFouw, D. O. (2001) · Tissue and Cell · doi:10.1054/tice.2000.0151 · Cited by 7
Applications of Inhibitors for Protein Kinase C and Their Isoforms
Shen, G. X., Way, K. J., Jacobs, J. R. C., & King, G. L. (2003) · Humana Press eBooks · doi:10.1385/1-59259-397-6:397 · Cited by 7
Self-citationDiagnosis, Management, and Treatment of Nonproliferative Diabetic Retinopathy
Aiello, L. P., Cavallerano, J. D., Prakash, M., & Aiello, L. M. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-0016-7.50136-3 · Cited by 7
Self-citationPathogenesis of Diabetic Microvascular Complications
He, Z., Rask‐Madsen, C., & King, G. L. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0901 · Cited by 7
Self-citationOgata, M., & YAMAZAKI, Y. (1979) · PubMed · doi:10.18926/amo/32049 · Cited by 7
Lin, C., Merley, A., & Jaminet, S.-C. S. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12031 · Cited by 6
“As TM4SF1 knockdown does not affect VEGFR2 protein levels (Figure 3), the inability of endothelial PKC α and PKC β are the two principal conventional Ca 2 þ ‐ dependent PKC isoforms in endothelial cells 35 and produce cascade activation of MEK and ERK for the regulation of cell proliferation.”
Backgroundα-Methyl-prednisolone normalizes the PKC mediated brain angiogenesis in dystrophic mdx mice
Annese, T., Ruggieri, S., Giorgis, M. D., Ribatti, D., Tamma, R., & Nico, B. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.023 · Cited by 6
Retinal Neovascularization and the Role of VEGF
Duh, E. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-563-3_15 · Cited by 6
“In bovine aortic endothelial cells, pharmacologic inhibition of PKC-β using the isoform selective inhibitor ruboxistaurin (LY333531) inhibited VEGF’s mitogenic effect ( 86 ).”
BackgroundMethodTargeting PKC‐β II and PKB Connection: Design of Dual Inhibitors
Jain, K., Ajay, D., & Sobhia, M. E. (2011) · Molecular Informatics · doi:10.1002/minf.201000082 · Cited by 6
Li, X., Fang, X., Li, S., Zhang, W., Yang, N., Cui, Y., Huang, H., Cai, R., Lin, X., Fu, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7875 · Cited by 6
“It is also a pivotal component in the B-cell receptor and vascular endothelial growth factor (VEGF) signaling pathways, which correlate to B-cell survival and VEGF-induced tumor angiogenesis, respectively [5–8].”
BackgroundConnexin37 Regulates Cell Cycle in the Vasculature
Fang, J. S., & Burt, J. M. (2022) · Journal of Vascular Research · doi:10.1159/000525619 · Cited by 6
Signal Transduction Therapy of Diabetic Vascular Complication
Yamagishi, S., Nakamura, K., Matsui, T., Yoshida, Y., Takenaka, K., Jinnouchi, Y., & Imaizumi, T. (2007) · Current Signal Transduction Therapy · doi:10.2174/157436207779317100 · Cited by 6
Pathophysiology of Diabetic Retinopathy
Lobanovskaya, N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100588 · Cited by 7
Microcirculatory Exchange Function
Durán, W. N., Sánchez, F. A., & Breslin, J. W. (2008) · Comprehensive physiology · doi:10.1002/cphy.cp020404 · Cited by 6
Microvascular Consequences of Obesity and Diabetes
Bohlen, H. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374530-9.00021-8 · Cited by 5
A PKC-beta inhibitor prompts the HUVECs apoptosis-induced by advanced glycation end products
Wang, S., Xu, Y., Feng, L., Zhu, Q., & He, B. (2011) · Die Pharmazie · doi:10.31083/ph.2011.0861 · Cited by 5
Rechka, A., Neagoe, P., Gratton, J., & Sirois, M. G. (2010) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y10-064 · Cited by 5
“This latter observation is in agreement with those of previous studies reporting that eNOS is a Ca2+/ calmodulin (Ca2+/CaM)-dependent enzyme, which is activated by intracellular Ca2+ release upon PLC-g activation (Busse and Mülsch 1990; Brock et al. 1991; Xia et al. 1996; Wu et al. 1999).”
ResultPituitary Expression of Protein Kinase C Isotypes During Early Development
Korytko, A. I., Fields, A. P., Allshouse, L. A., & Cuttler, L. (1998) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1998.00201.x · Cited by 5
Effect of Diabetes on Endothelial Function
Naruse, K., & King, G. L. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-091-9_3 · Cited by 5
Self-citationVEGF Signaling: A Therapeutic Target for Cardiovascular Disease
Dhanya, C. R., Gopalakrishnan, A. R. K., & Kartha, C. S. (2008) · Springer eBooks · doi:10.1007/978-0-387-09552-3_16 · Cited by 4
Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
Karttunen, T., Nummelin, L., Kaarniranta, K., & Kinnunen, K. (2019) · Clinical ophthalmology · doi:10.2147/opth.s232549 · Cited by 4
“Activation of protein kinase C by vascular endothelial growth factor (VEGF) is significant in DMO formation.(4,5) Furthermore, inflammation is considered to be present in DMO and it is an important factor in BRB breakdown.”
BackgroundAjiboye, B. O., Oyinloye, B. E., Udebor, E. A., Owolabi, O. V., Ejeje, J. N., Onikanni, S. A., & Omotuyi, O. I. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07657-x · Cited by 4
“Glucose metabolism produces superoxide anion (O2−) in the mitochondria, which can be transformed to hydroxyl radical (OH*) and hydrogen peroxide (H2O2) via the electron transport chain (ETC) [30, 28].”
BackgroundGrading of Diabetic Retinopathy
Larsen, M., Soliman, W. M., Kern, T. S., Mohr, S., Girach, A., Fong, D. S., Lang, G. E., Helbig, H., Joussen, A. M., Adamis, A. P., et al. (2007) · Springer eBooks · doi:10.1007/978-3-540-29542-6_19 · Cited by 4
Hanauske, A.-R., Eismann, U., Oberschmidt, O., Pospisil, H., Hanauske-Abel, H. M., Blatter, J., Ma, D., Chen, V., & Lahn, M. M. F. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9095-y · Cited by 4
Biologic therapy for malignant glioma
Chang, S. M., & Johnson, D. R. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06967-3.00006-5 · Cited by 4
Receptor Tyrosine Kinases in Angiogenesis
Shawver, L. K., Lipson, K. E., Fong, T. A. T., McMahon, G., & Strawn, L. M. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-126-8_22 · Cited by 4
Antagonising the expression of VEGF in pathological angiogenesis
Brenchley, P. E. (1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.12.1695 · Cited by 4
Growth factor antagonists for the treatment of diabetic vascular complications
Tilton, R. G., Dixon, R. A. F., & Brock, T. A. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.11.1671 · Cited by 4
Desroches‐Castan, A. (2014) · theses.fr (ABES) · doi:10.70675/e5d7d2abz4baez4e3dz97bbze95f10767efe · Cited by 4
Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review
Jain, R., & Daigavane, S. V. (2024) · Cureus · doi:10.7759/cureus.56796 · Cited by 3
“The signaling cascade of VEGF involves the activation of numerous downstream pathways after the binding of VEGF ligands to their receptors, thereby eliciting gene expression induction, regulation of vascular permeability, cell migration, proliferation, and survival [14].”
BackgroundSchöffel, N., Wahrlich, N., Bauer, J., Bendels, M. H. K., & Groneberg, D. A. (2015) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-015-0082-4 · Cited by 3
Mechanisms Linking Obesity and Leukemia Prognosis
Mittelman, S. D., & Butturini, A. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2403-1_3 · Cited by 3
The Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Breier, G., Damert, A., Blum, S., Reichmann, E., Plate, K. H., & Risau, W. (1998) · Springer eBooks · doi:10.1007/978-1-4899-1352-4_23 · Cited by 3
Effects of Diabetes and Insulin Resistance on Endothelial Functions
He, Z., Naruse, K., & King, G. L. (2005) · Humana Press eBooks · doi:10.1385/1-59259-908-7:025 · Cited by 3
“The use of the PKCβ selective inhibitor LY333531 can decrease endothelial cell proliferation, angiogenesis, and permeability induced by VEGF (145,146).”
BackgroundInfluentialSelf-citationRetinal Angiogenesis and Growth Factors
de Almodóvar, C. R., Ny, A., Carmeliet, P., King, G. L., Suzuma, K., Sun, J. K., Agostini, H. T., & Martin, G. (2007) · Springer eBooks · doi:10.1007/978-3-540-29542-6_3 · Cited by 3
Self-citationProtein kinase C inhibition in diabetic retinopathy and microvascular disease
Walton, C., Ryder, R. E. J., & Girach, A. (2007) · Practical Diabetes · doi:10.1002/pdi.1116 · Cited by 3
Kizub, I. V., Oi, K., Kostiuk, O., Остапченко, Л. І., & Soloviev, A. I. (2017) · Regulatory Mechanisms in Biosystems · doi:10.15421/021745 · Cited by 3
“Production of vasoactive eicosanoid PGE2 can be also increased in diabetic vessels (Xia et al., 1996).”
BackgroundÉpidémiologie et physiopathologie de la rétinopathie diabétique
Dupas, B., Massin, P., Gaudric, A., & Pâques, M. (2012) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(12)51215-1 · Cited by 3
Alonso, M. A. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2013.tde-05062013-141143 · Cited by 3
Synthesis and isozyme selectivity of small molecule protein kinase C inhibitors: a review of patents
Sridhar, J., & Pattabiraman, N. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.12.1691 · Cited by 3
“PKCβ, which is an important mediator of vascular endothelial growth factor (VEGF), plays an important role in tumour angiogenesis [19,20].”
BackgroundIntraocular Neovascularization
Young, T. A., & Miller, J. W. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02598-0.50147-6 · Cited by 3
Effects of Diabetes and Insulin Resistance on Endothelial Functions
Fu, J., Yu, M. G., Li, Q., Park, K., & King, G. L. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_3 · Cited by 2
Self-citationAsl, Z. S., Ghalichi, F., Badpeyma, M., & Ghoreishi, Z. (2024) · BioSocial Health Journal. · doi:10.34172/bshj.16 · Cited by 2
“37 Finally, the activation of PKC causes the damage of the carriers of endothelial cells in renal glomerular capillaries and, therefore, the permeability of the vessels rises.”
Mechanisms of Thrombocytosis in Iron‐Deficiency Anemia
Facco, J. V., Krause, D. S., & Saad, S. T. O. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70211 · Cited by 2
Ma, P., (18005), Y. G., Wang, H., Jiang, X., Tang, Y., Gong, M., Gong, J., Dong, H., & Su, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108283 · Cited by 2
Lorenzo, M. S. D., Fariña, H. G., Alonso, D. F., & Gomez, D. E. (2004) · PubMed · Cited by 2
Management of Diabetic Retinopathy. An Overview
Gotzaridis, E. V., Markou, A., & Gregor, Z. J. (2004) · HORMONES · doi:10.14310/horm.2002.11117 · Cited by 2
Metadata
- Authors
- Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L.
- Affiliations
- Joslin Diabetes Center (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2018-2026
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507645
- OpenAlex
- W2075553837
- Cited by
- 566
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 14 · 2013: 21 · 2012: 19
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (5r01dk036433-10, 5r29ey010827-04, 5r01ey005110-18, EY05110)
- National Eye Institute (EY10827, EY05110)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK36433)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- vascular endothelial growth factor, protein kinase C, PKC isoforms, PKC beta, endothelial cell proliferation, signal transduction, phospholipase C-gamma, phosphatidylinositol 3-kinase, diacylglycerol, ruboxistaurin, genistein, wortmannin, bovine aortic endothelial cells
- MeSH terms
- Animals, Cattle, Cell Division, Diglycerides, Endothelium, Vascular, Enzyme Activation, Inositol Phosphates, Isoenzymes, Lymphokines, Type C Phospholipases, Protein Kinase C, Signal Transduction, Endothelial Growth Factors, DNA, Antisense, Phosphotransferases (Alcohol Group Acceptor), Phosphotyrosine, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Phospholipase C gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.